Dose-modified lenalidomide induces sustained hematological response in patients with intermediate to high risk myelodysplasia. (2010). Mediterranean Journal of Hematology and Infectious Diseases, 2(2), e2010012. https://doi.org/10.4084/mjhid.2010.012